Roche pulls a tumor micro-environment drug out of the freezer, hands it to a UK upstart
Two years after pulling it from clinical development, Roche has handed control of a solid tumor cancer drug to a tiny Oxford University spinout.
For an undisclosed fee, Celleron Therapeutics acquired the drug, an anti-CSF1R antibody that’s designed to modulate the tumor micro-environment — an increasingly popular approach among cancer drug developers. Celleron says it will now put the drug into trials for patients with tenosynovial giant cell tumors, a rare disease where series of benign tumors begin to grow around the joints and tendons. It’s caused by cells over-producing CSF1R.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
